disease (eg, lipid keratopathy), 13 and neurologic conditions (eg, seizures). 14 Treatment options for preventing possible complications in dogs with IH include dietary modification with an ultra-low fat (ie, a diet with <20 g fat/1000 kcal). 1, 15 Lipid-lowering medical treatment options include ω-3 fatty acid supplements (eg, Menhaden fish oil), fibrates (eg, fenofibrate or gemfibrozil), or vitamin B 3 (niacin), but very few reports of their use in dogs are available and use of these approaches is mostly empirical. 1, 16, 17 Recent studies in people suggest that IH is associated with a lowgrade inflammatory reaction and endothelial dysfunction, which are suspected to play a role in the pathogenesis of secondary conditions associated with IH. 18, 19 The risk of such complications (eg, cardiovascular disease) also has been shown to decrease with medical control of IH in people. 20 Inflammatory mediators that have been shown to be altered in people with IH include C-reactive protein (CRP), interleukin 1 beta, tumor-necrosis factor alpha (TNF-α), and nuclear factor "kappa-light-chain-enhancer" of activated B cells (NF-κB). 21, 22 In MS with IH, the role of systemic inflammation has not been evaluated to date. Biomarkers of inflammation that are available in dogs include the positive type II acute reactant CRP, 23, 24 the S100A8/A9
protein (calprotectin) complex, 25 and S100A12 26 as markers of mononuclear or mixed type inflammation, bromotyrosine as a marker of eosinophilic inflammation, 27 and N-methylhistamine as a marker of mast cell degranulation. 28 The calprotectin (S100A8/A9) complex has been linked to the risk of cardiovascular complications in people with dyslipidemia. 29, 30 Furthermore, macrophage-mediated pancreatic beta-cell dysfunction because of increased fatty acid and glucose concentrations (glucolipotoxicity) has been shown to be associated with activation of the S100A8/Toll-like receptor-4 pathway and has been proposed to play an important role in systemic inflammation in people. 30 Determining the role of the S100/calgranulins (S100A8/A9 and S100A12) in the pathophysiology of spontaneous IH in dogs also will serve as a good model for human IH, because homologs of all 3 calgranulins are expressed in dogs, whereas rodents lack S100A12, 31 with S100A8 appearing to resemble S100A12 functionally. 32, 33 Given that biomarkers of inflammation have not yet been investigated in MS with IH, the aims of our prospective, observational clinical case-control study were to evaluate serum calprotectin (S100A8/A9) and S100A12 concentrations in healthy MS, MS with IH, and MS with IH after switching to an ultra-low fat diet. We hypothesized (1) that serum calprotectin or S100A12 concentrations or both are increased in MS with IH compared to healthy normolipidemic MS and (2) that serum calprotectin or S100A12 concentrations or both in MS with IH decrease with dietary intervention (ie, switching the dogs to an ultra-low fat diet). In addition, the possibilities of an effect of hyperlipidemia on serum calprotectin concentrations and an association with increased serum canine-specific pancreatic lipase concentrations (as a biochemical marker for pancreatitis)
were evaluated.
| MATERIALS AND METHODS

| Lipidemia interference testing
Previously, we have shown that hyperlipidemia does not appear to interfere with the measurement of S100A12 concentrations in serum samples, but centrifugation to remove excess lipids from serum was shown to result in lower S100A12 concentrations. 25 The possibility of hyperlipidemia interfering with the measurement of calprotectin in canine serum specimens was further evaluated by spiking 7 different surplus canine serum samples (with low, moderate, and high calprotectin concentrations) with known concentrations (0, 100, 250, 500, 750, 1100, 1250, 1500, 1750, 2000, and 3000 mg/dL) of a commercially available IV lipid formulation (Liposyn II 20% Intravenous lipid emulsion, Hospira, Lake Forest, Illinois) followed by measurement of calprotectin concentrations in all samples. The same serum samples also were used to quantify serum calprotectin and S100A12 concentrations by use of established and validated species-specific in-house radioimmunoassays. 25, 35 The RIs used for serum calprotectin and S100A12 concentrations were 72-234 and 33-225 μg/L, respectively. 25, 26 In addition, serum-specific pancreatic lipase concentrations were measured in all serum samples (RI, 0-200 μg/L). Multivariate logistic regression models with a stepwise forward model selection using Akaike's information criterion with a Wald Chisquare statistic for each effect in the model were constructed to evaluate the effect of selected (and if necessary log 10 -transformed) variables (where P < .2 in univariate analyses) on hyperlipidemia or increased serum calprotectin concentrations.
| Ethics approval
| Sample analysis
Statistical significance was set at P < .05, and Holm's sequential Bonferroni correction 37 was applied for multiple comparisons of paired data, with consideration of the numbers of categories (P corr = unad-
, where n is the number of hypotheses tested and k is the ordered rank of the uncorrected P values).
3 | RESULTS
| Interference of lipidemia with calprotectin measurement
Compared to unspiked samples, serum calprotectin concentrations were significantly altered when samples were spiked with IV lipid emulsion at concentrations of 1250, 1500, 1750, 2000, and 3000 mg/dL ( Figure 2 ).
The total coefficient of variation (CV) for all spiked solutions from each sample ranged from 3.0 to 17.8% (mean, 10.6%). Tables 1 and 2 . No significant differences in serum total T4, cTSH, free T4, serum Spec cPL, or serum cortisol concentrations were found between dogs with IH and normolipidemic dogs (Table 1) , nor were any differences in these variables found among dogs with HTGL, HCHOL, and combined hyperlipidemia ( 
|
| Dogs with IH included in the study (n = 71)
A total of 51 (72%), 7 (10%), and 13 MS (18%) had isolated HTGL, HCHOL, and combined hyperlipidemia, respectively ( Figure 1 ; Table 2 ).
Body weight and BCS did not differ among MS with isolated HTGL, HCHOL, and combined hyperlipidemia (P univariate = .78 and P univariate = .23, respectively), but dogs with HTGL were significantly older than those with isolated HCHOL (P multivariate = .003; Table 2 ).
| Serum calprotectin and S100A12 concentrations in MS with IH
Serum calprotectin concentrations were significantly higher in MS with IH (P multivariate < .001) compared to normolipidemic dogs, whereas the difference in S100A12 concentrations between those 2 groups of dogs was significant only during univariate analysis (P univariate = .04; Table 1 , Figure 3 ). Idiopathic hyperlipidemia was significantly associated with a higher percentage of serum calprotectin concentrations above the RI (P < .001; OR, 4.5; 95% CI, 1.9-10.9), but not with increased serum S100A12 concentration (P = .25; Table 1 , Figure 4 ).
No significant difference was found in serum calprotectin or serum S100A12 concentrations among MS with isolated HTGL, HCHOL, or combined hyperlipidemia (P univariate = .52 and P univariate = .52, respectively; Table 2 , Figure 3 ). Also, no significant differences in serum calprotectin or S100A12 concentrations were found in dogs with severe was significantly associated with increased serum S100A12 concentration (P = .18; OR, 1.7; 95% CI, 0.8-3.8; and P = .87, OR, 0.9; 95% CI, 0.3-2.9, respectively).
| Serum calprotectin and S100A12 concentrations after dietary intervention for IH
Of the 17 MS with IH included in this part of the study (Table 3) ultra-low fat diet (P corr = .03 and P = .003). Dietary intervention also yielded a significant decrease in serum cholesterol concentrations (P corr = .02; Table 3 ).
Neither serum calprotectin nor serum S100A12 concentrations changed significantly after dogs were placed on the ultra-low fat diet, nor did the proportion of dogs with increased serum calprotectin, S100A12, or both concentrations change (all P corr > .05; Table 3 ).
Serum Spec cPL concentrations and the proportion of dogs with increased serum Spec cPL concentration also were unchanged after feeding the ultra-low fat diet (all P corr > .05; Table 3 ). 
| DISCUSSION
We found an association between idiopathic IH in MS and increased serum calprotectin concentrations, with a weaker association detected between idiopathic IH and increased serum S100A12 concentrations.
Neither serum calprotectin nor serum S100A12 concentrations changed with successful dietary intervention in a subgroup of MS with
HTGL (with or without HCHOL).
Spiking experiments served to verify reliable measurement of serum calprotectin in dogs with marked hyperlipidemia. Although a statistically significant difference was found between serum calprotectin concentrations in unspiked samples and samples spiked with an intralipid concentration ≥1250 mg/dL, the overall CVs for all samples (3.0%-17.8%) were within acceptable limits for intraassay and interassay analytical variability of immunoassays (<20%). 38 Thus, serum calprotectin concentrations appear not to be affected by increased amounts of lipids.
We showed that hypercalprotectinemia consistent with subclinical associated with oxidative stress, low-grade systemic inflammation, and an increased risk of systemic complications. 19, 22, 39 Thus, further studies are warranted to evaluate if macrophage and neutrophil hyperactivity accounts for the increased serum S100/calgranulin concentrations in MS with IH. Further research also is warranted to determine whether this presumed low-grade inflammatory phenotype in MS with IH contributes to or reflects the development of possible complications of IH, 22, 39, 40 and to test the alternative hypothesis that the hypercalprotectinemia in MS with IH reflects an anti-inflammatory response.
In our study, a stronger association of serum calprotectin (S100A8/ A9) concentration was seen with HTGL compared to HCHOL in MS. This finding is also consistent with a study in people with combined IH where a stronger association was seen between the pro-inflammatory biomarker hsCRP and serum triglyceride concentrations compared to serum cholesterol concentrations. 18 The finding that MS with IH, particularly those with HTGL, were older than normolipidemic MS agrees with a previous study supporting that IH is a slow-onset, older-age condition in MS. 2 However, the detection of primary HCHOL without HTGL in approximately 5% of MS in our study contrasts with the results of a previous investigation in MS that did not report any cases of isolated HCHOL. 1,2 A possible explanation for this discrepancy could be a difference in the populations of dogs in both studies. However, although every effort was made to exclude dogs with a condition known to cause secondary hyperlipidemia, the possibility of missing an occult or rare cause of secondary hyperlipidemia 41, 42 cannot be entirely excluded.
Lack of an association between serum calprotectin concentration and BCS in our study differs from results in nondiabetic people where body mass index (BMI) independently determined serum calprotectin concentrations. 43, 44 However, calculation and interpretation of human BMI (which considers body weight, height, and also age) 45 is more objective than the 1-5 or 1-9 scale BCS currently used in veterinary medicine. 46 In addition, the majority of MS (128/139, 92%) had a BCS between 4 and 6/9 and only 7 MS were overweight or obese (BCS > 6/9). This may have prevented finding a link between BCS and serum calprotectin concentrations in our study. Furthermore, a confounder might be the fact that diabetes mellitus associated with higher BMI is typically type 2 in humans;
whereas, in dogs, it is usually type 1 diabetes mellitus.
No association was found between increased serum Spec cPL concentrations and hypercalprotectinemia in our study. However, only 22 MS (15%) had a serum Spec cPL concentration above the RI (ie, 200 μg/L), with only 11 MS (8%) having a serum Spec cPL Idiopathic HTGL in MS has been reported to be associated with proteinuria 11, 40 and ultrastructural glomerular lesions, 12 but whether these findings are a consequence or cause of dyslipidemia in MS remains unknown. Presence of proteinuria (ie, urine protein/creatinine ratios) or renal biopsy specimens were not evaluated in our study. Thus, the possibility of an association between increased serum calprotectin concentrations and proteinuria, glomerular lesions, or both cannot be evaluated.
Lack of a decrease in serum calprotectin or S100A12 concentrations with successful dietary intervention (ie, feeding an ultra-low fat diet over 3-6 months) in MS with IH was an unexpected finding.
These results contrast with the beneficial effect of lipid-lowering medications on serum hsCRP, IL-1β, and soluble CD40 ligand (sCD40L) concentrations in human patients with combined hyperlipidemia. 21 However, our results agree with the lack of a change in the concentrations of other inflammatory markers (CRP, sICAM, fibrinogen, IL-1β, TNF-α, sCD40L, or combinations of these) seen in people diagnosed with either combined hyperlipidemia or familial HCHOL and who received either diet-only or an intensive or long-term lipid-lowering medical treatment. 19, [47] [48] [49] Our results could suggest an inflammatory FIGURE 4 Association between idiopathic hyperlipidemia (IH) and increased serum calprotectin and S100A12 concentrations in clinically healthy MS (n = 150). (A) There was a significant association between IH and a serum calprotectin concentration increased above RI (P < .001), (B) which was not seen for serum S100A12 concentration (P = .25). (C) There was also a significant independent association of serum calprotectin concentrations increased above RI with HTGL (P < .001; OR, 4.0; 95% CI, 1.7-9.2) and (D) HCHOL (P = .01; OR, 3.7; 95% CI, 1.4-10.0). HCHOL, hypercholesterolemia; HTGL, hypertriglyceridemia phenotype being present in some MS with IH despite a successful lipid-lowering dietary strategy. However, whether a longer treatment interval might be needed for any changes in serum S100/calgranulin concentrations or if additional lipid-lowering medications are warranted in these dogs requires further studies. Also, the relationship between the inflammatory markers evaluated in our study and evidence of insulin resistance 8, 22 should be evaluated in MS with IH.
We acknowledge that our study had some limitations. Although common causes of secondary hyperlipidemia were ruled out, the possibility of occult or rare diseases (eg, lymphoma) cannot be definitively excluded in all dogs as a cause of hyperlipidemia. Also, single serum samples were evaluated, and the biological variation of serum triglycer- the acute-phase protein CRP) with a spatial or temporal expression or both that differs from that of the S100/calgranulins were not evaluated.
Lastly, small sample size (especially in various subgroup analyses) could result in potential for type I or type II error.
| CONCLUSIONS
Our results suggest that low-grade subclinical inflammation might be present in approximately every third clinically healthy MS with IH (characterized by HTGL, HCHOL, or both), and that feeding an ultralow fat diet for 3-6 months does not appear to decrease the serum concentrations of the inflammatory S100/calgranulin proteins in hypertriglyceridemic MS with or without HCHOL. Whether this presumed inflammatory phenotype in MS with IH plays a role in the development of possible complications of IH (eg, insulin resistance, pancreatitis, or other conditions) warrants further research. Also, IH in MS appears to be a good spontaneous animal model for studying the S100/calgranulins in people with familial hyperlipidemia where rodent models cannot be utilized. 
